source
- Kymera Therapeutics to unveil mid‑stage eczema trial data, aiming to challenge DupixentKymera Therapeutics, a Massachusetts‑based biotech, is set to release data from its mid‑stage clinical trial of KT‑621 in eczema before the end of 2026. The trial results are being closely watched…
- Karyopharm files for Chapter 11 and plans auction with Gamida Cell parent Ayrmid as lead bidderKaryopharm Therapeutics, a cash-strapped cancer drugmaker, announced a Chapter 11 filing on Monday and will conduct a court-supervised auction of the company. Ayrmid, the parent of cell-therapy co…